Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PolyMedix completes Phase I safety study of new antibiotic drug
The data from the study demonstrate that safe and well-tolerated single doses were achieved at suggested levels and that a beneficial therapeutic index may be possible. Further clinical
The data from the study demonstrate that safe and well-tolerated single doses were achieved at suggested levels and that a beneficial therapeutic index may be possible. Further clinical
Under the terms of the agreement, Helsinn Healthcare will receive a worldwide exclusive license to ZP1846 and will be responsible for all further development, regulatory approvals, manufacturing, marketing
Approximately $8 million in cash will be retained from current Dow accounts, making the net amount paid $277 million. Valeant will make the first payment of $250 million
According to the company, these actions are being taken to manage capital resources while Panacos pursues strategic alternatives, including the financing, partnering or sale of the company or
Crofelemer is Napo’s novel anti-secretory, gastrointestinal agent currently in a final Phase III trial for the treatment of chronic diarrhea in people living with HIV/AIDS (the ADVENT program)
KAI’s double-blind, randomized, placebo- and active-comparator-controlled, single-dose study will evaluate the efficacy of KAI-1678 administered by subcutaneous infusion for the treatment of postoperative pain. The primary endpoint of
The content and schedule for submitting the modules, which represent major sections of the entire premarket approval (PMA) application, were agreed to in advance by Guided Therapeutics (GT)
The vote was 16 against, one in favor and one abstention. The committee also discussed concerns that it would like addressed to support approval of the product for
The preclinical study compared Crucell’s monoclonal antibody (mAb) CR6261 with the anti-influenza drug oseltamivir in terms of their value for flu prevention and treatment. The flu strains tested
Early analysis of the Phase II multiple myeloma (MM) study, in which half of the 60 patients with relapsed MM received combined low-dose dexamethasone with pomalidomide, showed that